Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
AC
Adicet Bio, Inc. Common Stock
ACET
Mkt Cap
$43.0M
Volume
177.51K
Next Earnings
November 4th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
AC
ACET
AC
Adicet Bio, Inc. Common Stock
ACET
News
·
Lupus Nephritis Clinical Trial Landscape Becomes Increasingly Crowded with 30+ Pharma Companies | DelveInsight
Mkt Cap
$48.1M
Volume
177.51K
Next Earnings
November 4th
Chart
Financials
Earnings
News
About
Insider
Filings
Lupus Nephritis Clinical Trial Landscape Becomes Increasingly Crowded with 30+ Pharma Companies | DelveInsight
The lupus nephritis drug development pipeline is rapidly expanding with 30+ pharmaceutical companies developing 35+ pipeline therapies across various clinical stages. Key players including Novartis, Simcere Pharmaceutical, Kyverna Therapeutics, Century Therapeutics, and Adicet Bio are advancing promising treatments with novel mechanisms of action such as BAFF-R inhibitors, CAR-NK cell therapies, and anti-CD19/CD20 approaches. Recent regulatory milestones include FDA RMAT designations for cell therapies and positive Phase III trial results, indicating accelerating progress in addressing this serious autoimmune kidney disease.
GlobeNewswire Inc. · Jun 10, 2026
Johnson & Johnson Touts Encouraging Results For Experimental Lupus Treatment
Johnson & Johnson announced positive Phase 2b results for nipocalimab, an experimental FcRn blocker for treating systemic lupus erythematosus (SLE). The JASMINE study of 228 subjects met its primary endpoint and key secondary endpoints, with a favorable safety profile. The company plans to initiate Phase 3 trials. The lupus treatment market includes competing programs from UCB/Biogen, Cartesian Therapeutics, and Adicet Bio.
Benzinga · Jan 6, 2026
The Royal Office of H.H. Sheikh Ahmed Bin Faisal Al-Qassimi and ACET ($ACT) Drive Blockchain Payment Innovation in UAE’s $3.9 Billion USD Initiative
ACET ($ACT), a blockchain-powered DeFi platform, has partnered with the Royal Office of H.H. Sheikh Ahmed Bin Faisal Al-Qassimi to drive blockchain adoption and financial innovation in the UAE, including integrating ACET ($ACT) into a $3.9 billion casino resort project.
GlobeNewswire Inc. · Mar 25, 2025
ACET Founder Acme Proposes Using Bitcoin Integration to Transform Thailand Economy
Acme Worawat, founder of the ACET (ACT) digital currency, has proposed integrating Bitcoin into Thailand's economic framework, including utilizing it as part of the country's reserve fund. The initiative aims to position Thailand as a global leader in Blockchain technology and attract global crypto investments.
GlobeNewswire Inc. · Dec 26, 2024
Why Adicet Bio (ACET) Stock Might be a Great Pick
Adicet Bio (ACET) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Zacks Investment Research · Apr 4, 2024
Evaxion (EVAX) Up on Upbeat Preclinical S. Aureus Vaccine Data
Evaxion (EVAX) gains 20% on positive results from the pre-clinical studies of its EVX-B1 vaccine candidate in large non-rodent animals, which is being developed to treat S. aureus infection.
Zacks Investment Research · Apr 3, 2024
Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year?
Here is how Adicet Bio, Inc. (ACET) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
Zacks Investment Research · Apr 1, 2024
Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why
Apogee (APGE) surges 95.6% in a month after reporting positive interim results from its phase I study for APG777 to treat AD. The company plans to initiate a phase II study for the same indication.
Zacks Investment Research · Mar 28, 2024
Akebia (AKBA) Up as Vafseo Gets FDA Nod for Anemia Due to CKD
Akebia (AKBA) gains during premarket hours on Mar 28 as its key product Vafseo (vadadustat) tablets receive FDA's approval for the treatment of anemia due to chronic kidney disease.
Zacks Investment Research · Mar 28, 2024
Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data
Stoke Therapeutics (STOK) gains on meaningful clinical data from STK-001 studies for the treatment of Dravet syndrome.
Zacks Investment Research · Mar 27, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
AC
ACET
Adicet Bio, Inc. Common Stock
Buy
Sell
Market
Limit
Soon
ACET
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any ACET yet.
Related Tickers
AD
ADMA
—
Earnings